Share
.webp)
.webp)
.webp)
.webp)
Emma Bush
CNX Therapeutics Limited has appointed Emma Bush as Vice President, Commercial.
Emma brings with her extensive global experience across the pharmaceutical, aesthetics, and consumer health sectors, positioning her to play a critical role in shaping and expanding CNX Therapeutics’ commercial strategy.
Most recently, Emma served as Head of Global Accounts & Business Services at Galderma SA, where she was responsible for driving strategic growth initiatives and managing key partnerships across diverse healthcare markets. Before Galderma, she held senior leadership roles at globally recognized companies, including GSK and Teva, where she established a strong track record in strategic account management, commercial development, and building sustainable business growth.
Emma holds an Executive MBA from Ashridge Business School, complementing her professional expertise with strong academic foundations in business leadership and strategy. Her breadth of experience in leading commercial operations at multinational organizations will be instrumental as CNX Therapeutics strengthens its presence in the specialty pharmaceutical sector.
CNX Therapeutics, which was acquired by Inflexion Private Equity in 2021, continues to focus on delivering innovative solutions in critical therapeutic areas. With Emma’s appointment, the company reinforces its commitment to advancing commercial excellence, driving market growth, and building strong partnerships that support its mission of improving patient outcomes worldwide.
.webp "TransCode Therapeutics Appoints Jack E. Stover to Board of Directors")
